Loading…

New strategies for the synthesis of A3 adenosine receptor antagonists

New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These comp...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2003-09, Vol.11 (19), p.4161-4169
Main Authors: BARALDI, Pier Giovanni, BOVERO, Andrea, FRUTTAROLO, Francesca, ROMAGNOLI, Romeo, MOJGAN AGHAZADEH TABRIZI, PRETI, Delia, VARANI, Katia, BOREA, Pier Andrea, MOORMAN, Allan R
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393
cites
container_end_page 4169
container_issue 19
container_start_page 4161
container_title Bioorganic & medicinal chemistry
container_volume 11
creator BARALDI, Pier Giovanni
BOVERO, Andrea
FRUTTAROLO, Francesca
ROMAGNOLI, Romeo
MOJGAN AGHAZADEH TABRIZI
PRETI, Delia
VARANI, Katia
BOREA, Pier Andrea
MOORMAN, Allan R
description New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers.
doi_str_mv 10.1016/S0968-0896(03)00484-X
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73601280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73601280</sourcerecordid><originalsourceid>FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393</originalsourceid><addsrcrecordid>eNpF0E1Lw0AQgOFFFFurP0HJRdFDdDa7SXaPpdQPKHpQobdls5mtkTapOynSf2_6gT3N5ZkZeBm75HDPgWcP76AzFYPS2S2IOwCpZDw9Yn0uMxkLofkx6_-THjsj-gaARGp-yno80SnnMu-z8Sv-RtQG2-KsQop8E6L2CyNa192giqLGR0MR2RLrhqoao4AOl23HbN3aWVNX1NI5O_F2TnixnwP2-Tj-GD3Hk7enl9FwErskhTbOLeRcaKWlKp1PnVK55yBLLCTXTgkpnRNp4UCXApXWHDLwPpXao9aF0GLAbnZ3l6H5WSG1ZlGRw_nc1tisyOQiA54o6GC6gy40RAG9WYZqYcPacDCbfmbbz2ziGBBm289Mu72r_YNVscDysLUP1oHrPbDk7NwHW7uKDi5NMqFUIv4AWxp3-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73601280</pqid></control><display><type>article</type><title>New strategies for the synthesis of A3 adenosine receptor antagonists</title><source>ScienceDirect Journals</source><creator>BARALDI, Pier Giovanni ; BOVERO, Andrea ; FRUTTAROLO, Francesca ; ROMAGNOLI, Romeo ; MOJGAN AGHAZADEH TABRIZI ; PRETI, Delia ; VARANI, Katia ; BOREA, Pier Andrea ; MOORMAN, Allan R</creator><creatorcontrib>BARALDI, Pier Giovanni ; BOVERO, Andrea ; FRUTTAROLO, Francesca ; ROMAGNOLI, Romeo ; MOJGAN AGHAZADEH TABRIZI ; PRETI, Delia ; VARANI, Katia ; BOREA, Pier Andrea ; MOORMAN, Allan R</creatorcontrib><description>New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(03)00484-X</identifier><identifier>PMID: 12951147</identifier><language>eng</language><publisher>Oxford: Elsevier Science</publisher><subject>Adenosine A3 Receptor Antagonists ; Animals ; Binding, Competitive ; Biological and medical sciences ; CHO Cells ; Cricetinae ; Drug Design ; Humans ; Isomerism ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Pyrazoles - chemistry ; Pyrimidines - chemical synthesis ; Pyrimidines - metabolism ; Pyrimidines - pharmacology ; Receptor, Adenosine A3 - metabolism ; Structure-Activity Relationship ; Triazoles - chemistry</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2003-09, Vol.11 (19), p.4161-4169</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15263882$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12951147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARALDI, Pier Giovanni</creatorcontrib><creatorcontrib>BOVERO, Andrea</creatorcontrib><creatorcontrib>FRUTTAROLO, Francesca</creatorcontrib><creatorcontrib>ROMAGNOLI, Romeo</creatorcontrib><creatorcontrib>MOJGAN AGHAZADEH TABRIZI</creatorcontrib><creatorcontrib>PRETI, Delia</creatorcontrib><creatorcontrib>VARANI, Katia</creatorcontrib><creatorcontrib>BOREA, Pier Andrea</creatorcontrib><creatorcontrib>MOORMAN, Allan R</creatorcontrib><title>New strategies for the synthesis of A3 adenosine receptor antagonists</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers.</description><subject>Adenosine A3 Receptor Antagonists</subject><subject>Animals</subject><subject>Binding, Competitive</subject><subject>Biological and medical sciences</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Drug Design</subject><subject>Humans</subject><subject>Isomerism</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrazoles - chemistry</subject><subject>Pyrimidines - chemical synthesis</subject><subject>Pyrimidines - metabolism</subject><subject>Pyrimidines - pharmacology</subject><subject>Receptor, Adenosine A3 - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>Triazoles - chemistry</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpF0E1Lw0AQgOFFFFurP0HJRdFDdDa7SXaPpdQPKHpQobdls5mtkTapOynSf2_6gT3N5ZkZeBm75HDPgWcP76AzFYPS2S2IOwCpZDw9Yn0uMxkLofkx6_-THjsj-gaARGp-yno80SnnMu-z8Sv-RtQG2-KsQop8E6L2CyNa192giqLGR0MR2RLrhqoao4AOl23HbN3aWVNX1NI5O_F2TnixnwP2-Tj-GD3Hk7enl9FwErskhTbOLeRcaKWlKp1PnVK55yBLLCTXTgkpnRNp4UCXApXWHDLwPpXao9aF0GLAbnZ3l6H5WSG1ZlGRw_nc1tisyOQiA54o6GC6gy40RAG9WYZqYcPacDCbfmbbz2ziGBBm289Mu72r_YNVscDysLUP1oHrPbDk7NwHW7uKDi5NMqFUIv4AWxp3-Q</recordid><startdate>20030915</startdate><enddate>20030915</enddate><creator>BARALDI, Pier Giovanni</creator><creator>BOVERO, Andrea</creator><creator>FRUTTAROLO, Francesca</creator><creator>ROMAGNOLI, Romeo</creator><creator>MOJGAN AGHAZADEH TABRIZI</creator><creator>PRETI, Delia</creator><creator>VARANI, Katia</creator><creator>BOREA, Pier Andrea</creator><creator>MOORMAN, Allan R</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030915</creationdate><title>New strategies for the synthesis of A3 adenosine receptor antagonists</title><author>BARALDI, Pier Giovanni ; BOVERO, Andrea ; FRUTTAROLO, Francesca ; ROMAGNOLI, Romeo ; MOJGAN AGHAZADEH TABRIZI ; PRETI, Delia ; VARANI, Katia ; BOREA, Pier Andrea ; MOORMAN, Allan R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenosine A3 Receptor Antagonists</topic><topic>Animals</topic><topic>Binding, Competitive</topic><topic>Biological and medical sciences</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Drug Design</topic><topic>Humans</topic><topic>Isomerism</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrazoles - chemistry</topic><topic>Pyrimidines - chemical synthesis</topic><topic>Pyrimidines - metabolism</topic><topic>Pyrimidines - pharmacology</topic><topic>Receptor, Adenosine A3 - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>Triazoles - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARALDI, Pier Giovanni</creatorcontrib><creatorcontrib>BOVERO, Andrea</creatorcontrib><creatorcontrib>FRUTTAROLO, Francesca</creatorcontrib><creatorcontrib>ROMAGNOLI, Romeo</creatorcontrib><creatorcontrib>MOJGAN AGHAZADEH TABRIZI</creatorcontrib><creatorcontrib>PRETI, Delia</creatorcontrib><creatorcontrib>VARANI, Katia</creatorcontrib><creatorcontrib>BOREA, Pier Andrea</creatorcontrib><creatorcontrib>MOORMAN, Allan R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARALDI, Pier Giovanni</au><au>BOVERO, Andrea</au><au>FRUTTAROLO, Francesca</au><au>ROMAGNOLI, Romeo</au><au>MOJGAN AGHAZADEH TABRIZI</au><au>PRETI, Delia</au><au>VARANI, Katia</au><au>BOREA, Pier Andrea</au><au>MOORMAN, Allan R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New strategies for the synthesis of A3 adenosine receptor antagonists</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2003-09-15</date><risdate>2003</risdate><volume>11</volume><issue>19</issue><spage>4161</spage><epage>4169</epage><pages>4161-4169</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>New A(3) adenosine receptor antagonists were synthesized and tested at human adenosine receptor subtypes. An advanced synthetic strategy permitted us to obtain a large amount of the key intermediate 5 that was then submitted to alkylation procedures in order to obtain the derivatives 6-8. These compounds were then functionalised into ureas at the 5-position (compounds 9-11, 18 and 19) to evaluate their affinity and selectivity versus hA(3) adenosine receptor subtype; in particular, compounds 18 and 19 displayed a value of affinity of 4.9 and 1.3 nM, respectively. Starting from 5, the synthetic methodologies employed permitted us to perform a rapid and a convenient divergent synthesis. A further improvement allowed the regioselective preparation of the N(8)-substituted compound 7. This method could be used as an helpful general procedure for the design of novel A(3) adenosine receptor antagonists without the difficulty of separating the N(8)-substituted pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines from the corresponding N(7)-isomers.</abstract><cop>Oxford</cop><pub>Elsevier Science</pub><pmid>12951147</pmid><doi>10.1016/S0968-0896(03)00484-X</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2003-09, Vol.11 (19), p.4161-4169
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_73601280
source ScienceDirect Journals
subjects Adenosine A3 Receptor Antagonists
Animals
Binding, Competitive
Biological and medical sciences
CHO Cells
Cricetinae
Drug Design
Humans
Isomerism
Medical sciences
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems
Pharmacology. Drug treatments
Pyrazoles - chemistry
Pyrimidines - chemical synthesis
Pyrimidines - metabolism
Pyrimidines - pharmacology
Receptor, Adenosine A3 - metabolism
Structure-Activity Relationship
Triazoles - chemistry
title New strategies for the synthesis of A3 adenosine receptor antagonists
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A20%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20strategies%20for%20the%20synthesis%20of%20A3%20adenosine%20receptor%20antagonists&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=BARALDI,%20Pier%20Giovanni&rft.date=2003-09-15&rft.volume=11&rft.issue=19&rft.spage=4161&rft.epage=4169&rft.pages=4161-4169&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(03)00484-X&rft_dat=%3Cproquest_cross%3E73601280%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c250t-7a071398948dcf5c887f104deb419c8344cc35bc09d3e8991060ff549fe99b393%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73601280&rft_id=info:pmid/12951147&rfr_iscdi=true